Effect of Validated Yoga Protocol in the management of Polycystic ovarian Syndrome - NI

Banaras Hindu University0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•Patients who satisfied the Rotterdam criterion (2/3 of the features) for PCOS will be included in the study. The following were the
•definitions of the three features. Oligo/amenorrhea: Absence of menstruation for 45 days or more and/or less than eight menses per
•Clinical hyperandrogenism, Modified Ferriman and
•Gallway (mFG) score of 6 or higher. Biochemical hyperandrogenism, serum LH and FSH ratio more than 2:1.
•Poly cystic ovaries: Presence of >10 cysts, 2-8 mm in diameter, usually combined with increased ovarian volume of >10 cm3, and an echo-dense stroma in pelvic ultrasound scan

•Patients who use of oral contraceptives/hormone
•treatment/insulin-sensitizing agents within
•previous six weeks.
•Patients who have addiction of alcohol, smoking and any prior experience of yoga.
•Patients who have Hyperprolactinemia, thyroid abnormalities and non-classic adrenal hyperplasia, and those who did not consent for the study.
•Patients who have Primary ammenorheoa, Premature ovarian failure, absent ovary and uterus.
•The patients suffering from diabetes mellitus, hypertension, thyroid disorders, hyperprolactinemia, congenital adrenal hyperplasia, other gynaecological disorders, and renal failure.
•Patients with evidence of malignancy.
•Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.)
•Patients who have a past history of Atrial Fibrillation, Coronary Artery Disease (CAD), Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•Symptomatic patient with clinical evidence of Heart failure.
•Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
•Patients who have completed participation in any other clinical trial during the past six (06) months.
•Any other condition which the doctor thinks may jeopardize the study.

发起方